# US 2003/0228304 A1 · Chimeric antibodies for delivery of antigens to selected cells of the immune system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0228304 A1
- Document ID: US20030228304A1
- Status: Published application
- Kind: A1
- Application number: 10/428,754
- Filed: 2003-05-05
- Published: 2003-12-11
- Earliest claimed: 1998-01-14
- Inventors: Naveen N. Anand; Brian H. Barber; George A. Cates; Judith E. Caterini; Michel H. Klein
- Web page: https://patentgrep.com/patent/US20030228304A1

## CPC

- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C07K 16/114: Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- A61K 2039/505: {comprising antibodies}
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antibody molecules specific for surface structures of antigen presenting cells that have been modified to include an antigen moiety at a specific site therein to produce novel conjugate antibody molecules are disclosed. These conjugate molecules are produced by genetic modification of genes encoding light and heavy chains of the surface structure specific antibody, and expression in mammalian cells to produce the conjugate antibody. The conjugate antibody retained specificity for antigen presenting cells and contained the antigen moiety. The conjugate antibody molecules deliver the antigen to antigen presenting cells to produce an enhanced immune response to a host immunized therewith. The conjugate antibody molecules and nucleic acid molecules encoding them are useful as antigens and as immunogene in diagnostic and prophylactic applications.

## Claims

### Claim 1

A recombinant conjugate antibody molecule, comprising a monoclonal antibody moiety specific for a surface structure of antigen presenting cells genetically modified to contain at least one antigen moiety exclusively at at least one preselected site on said monoclonal antibody moiety, whereby said conjugate antibody molecule is capable of delivering said antigen moiety to the antigen presenting cells of a host and capable of eliciting an immune response to said antigen moiety in the host.

### Claim 2 (depends on 1)

The molecule of claim 1 wherein said antigen presenting cells are selected from the group consisting of class I major histocompatibility expressing cells, class II major histocompatibility expressing cells, dendritic cells and CD4+ cells.

### Claim 3 (depends on 1)

The molecule of claim 1 wherein said at least one antigen moiety is located at at least one end of at least one of the heavy and light chains of said monoclonal antibody moiety.

### Claim 4 (depends on 3)

The molecule of claim 3 wherein said at least one antigen moiety is located at the C-terminal end of said at least one of the heavy and light chains of said monoclonal antibody moiety.

### Claim 5 (depends on 4)

The molecule of claim 4 wherein said at least one antigen moiety is located at the C-terminal end of both said heavy and light chains of said monoclonal antibody moiety.

### Claim 6 (depends on 5)

The molecule of claim 5 wherein said at least one antigen moiety is directly linked to the C-terminal end of both said heavy and light chains of said monoclonal antibody moiety.

### Claim 7 (depends on 6)

The molecule of claim 6 wherein said at least one antigen moiety is an inherently weakly-immunogenic antigen moiety.

### Claim 8 (depends on 6)

The molecule of claim 6 wherein said at least one antigen moiety comprises a plurality of antigen moieties.

### Claim 9 (depends on 8)

The molecule of claim 8 wherein said plurality of antigen moieties is a plurality of a single antigen moiety.

### Claim 10 (depends on 8)

The molecule of claim 8 wherein said plurality of antigen moieties is a plurality of different antigenic moieties.

### Claim 11 (depends on 7)

The molecule of claim 7 wherein said at least one antigen moiety is a peptide having from 6 to 100 amino acids and containing at least one epitope.

### Claim 12

A nucleic acid molecule, comprising a first nucleotide sequence encoding a chain of a monoclonal antibody specific for a surface structure of antigen-presenting cells selected from the group consisting of the heavy chain and the light chain of the monoclonal antibody, a second nucleotide sequence encoding at least one antigen and a third nucleotide sequence comprising a promoter for eukaryotic cell expression of a fusion protein comprising said monoclonal antibody chain and said at least one antigen.

### Claim 13 (depends on 12)

The nucleic acid molecule of claim 12 wherein said encoded chain is the heavy chain of the monoclonal antibody.

### Claim 14 (depends on 12)

The nucleic acid molecule of claim 12 wherein said encoded chain is the light chain of the monoclonal antibody.

### Claim 15 (depends on 12)

The nucleic acid molecule of claim 12 wherein antigen presenting cells are selected from the group consisting of class I major histocompatibility expressing cells, class II major histocompatibility expressing cells, dendritic cells and CD4+ cells.

### Claim 16 (depends on 12)

The nucleic acid molecule of claim 12 wherein said first nucleotide sequence and aid second nucleotide sequence are directly linked in a single transcriptional unit under control of said promoter.

### Claim 17 (depends on 16)

The nucleic acid molecule of claim 16 wherein said third nucleotide sequence is disposed at the 5′ end of said first nucleotide sequence.

### Claim 18 (depends on 12)

A vector comprising the nucleic acid molecule of claim 12.

### Claim 19 (depends on 18)

The vector of claim 18 containing a first nucleic acid molecule comprising a first nucleotide sequence encoding the heavy chain of a monoclonal antibody specific for a surface structure of antigen-presenting cells, a second nucleotide sequence encoding at least one antigen and a third nucleotide sequence comprising a promoter for eukaryotic cell expression of a fusion protein comprising said monoclonal antibody heavy chain and said at least one antigen as a first transcriptional unit, and a second nucleic acid molecule comprising a first nucleotide sequence encoding the light chain of a monoclonal antibody specific for a surface structure of antigen-presenting cells, a second nucleotide sequence encoding at least one antigen and a third nucleotide sequence comprising a promoter for eukaryotic cell expression of a fusion protein comprising said monoclonal antibody light chain and said at least one antigen as a second transcriptional unit.

### Claim 20 (depends on 19)

The vector of claim 19 having the characteristic properties of plasmid pCMVdhfr.chLCHC.

### Claim 21

A method of making a conjugate antibody molecule comprising a monoclonal antibody moiety specific for a surface structure of antigen-presenting cells and at least one antigen moiety, which comprises:
constructing a first nucleic acid molecule containing a first nucleotide sequence encoding a heavy chain of said monoclonal antibody and a second nucleotide sequence encoding at least one antigen,
constructing a second nucleotide acid molecule containing a first nucleotide sequence encoding a light chain of said monoclonal antibody and a second nucleotide sequence encoding said at least one antigen, and
coexpressing said first and second nucleic acid molecules in mammalian cells to form said conjugate antibody molecule.

### Claim 22 (depends on 21)

The method of claim 21 wherein said coexpression of said first and second nucleic acid molecules includes constructing an expression vector containing said first and second nucleic acid molecules as independent transcriptional units.

### Claim 23 (depends on 22)

The method of claim 22 wherein each said independent transcriptional unit includes a promoter operable in mammalian cells to direct said coexpression.

### Claim 24 (depends on 23)

The method of claim 23 wherein said expression vector has the characteristic properties of plasmid pCMVdhfr.chLCHC.

### Claim 25 (depends on 23)

The method of claim 23 wherein said coexpression includes secretion of said conjugate antibody molecule and further separating and purifying said conjugate antibody molecule.

### Claim 26 (depends on 25)

The method of claim 25 wherein said purification comprises binding of the conjugate antibody molecule to protein A and selective elution of said conjugate antibody molecule from protein A.

### Claim 27

An immunogenic composition, comprising a conjugate antibody molecule comprising a monoclonal antibody moiety specific for a surface structure of antigen presenting cells genetically modified to contain at least one antigen moiety exclusively at at least one preselected site on said monoclonal antibody moiety, whereby said conjugate antibody molecule is capable of delivering said antigen moiety to the antigen presenting cells of a host and capable of eliciting an immune response to said antigen moiety in the host or a nucleic acid molecule comprising a first nucleotide sequence encoding a chain of a monoclonal antibody specific for a surface structure of antigen-presenting cells selected from the group consisting of the heavy chain and the light chain of the monoclonal antibody, a second nucleotide sequence encoding at least one antigen and a third nucleotide sequence comprising a promoter for eukaryotic cell expression of a fusion protein comprising said monoclonal antibody chain and said at least one antigen.

### Claim 28 (depends on 27)

The immunogenic composition of claim 27 formulated as a vaccine for in vivo administration to a host to confer protection against disease caused by a pathogen producing said at least one antigen.

### Claim 29

A method of generating an immune response in a host, comprising administering thereto an immuno-effective amount of an immunogenic composition comprising a conjugate antibody molecule comprising a monoclonal antibody moiety specific for a surface structure of antigen presenting cells genetically modified to contain at least one antigen moiety exclusively at at least one preselected site on said monoclonal antibody moiety, whereby said conjugate antibody molecule is capable of delivering said antigen moiety to the antigen presenting cells of a host and capable of eliciting an immune response to said antigen moiety in the host or a nucleic acid molecule comprising a first nucleotide sequence encoding a chain of a monoclonal antibody specific for a surface structure of antigen-presenting cells selected from the group consisting of the heavy chain and the light chain of the monoclonal antibody, a second nucleotide sequence encoding at least one antigen and a third nucleotide sequence comprising a promoter for eukaryotic cell expression of a fusion protein comprising said monoclonal antibody chain and said at least one antigen.

### Claim 30

A method of determining the presence of a selected antigen in a sample, which comprises:
(a) immunizing a host with a conjugate antibody molecule, comprising a monoclonal antibody moiety specific for a surface structure of antigen presenting cells genetically modified to contain at least one antigen moiety exclusively at at least one preselected site on said monoclonal antibody moiety, whereby said conjugate antibody molecule is capable of delivering said antigen moiety to the antigen presenting cells of a host and capable of eliciting an immune response to said antigen moiety in the host, wherein said at least one antigen moiety is said selected antigen to produce antibodies specific to said selected antigen;
(b) isolating said antibodies;
(c) contacting the sample with the isolated antibodies to produce complexes comprising any selected antigen in the sample and said selected antigen-specific antibodies; and
(d) determining production of the complexes.

### Claim 31

A diagnostic kit for determining the presence of a selected antigen in a sample, comprising:
(a) a conjugate antibody molecule comprising a monoclonal antibody moiety specific for a surface structure of antigen presenting cells genetically modified to contain at least one antigen moiety exclusively at at least one preselected site on said monoclonal antibody moiety, whereby said conjugate antibody molecule is capable of delivering said antigen moiety to the antigen presenting cells of a host and capable of eliciting an immune response to said antigen moiety in the host, wherein the at least one antigen moiety is said selected antigen;
(b) means for detecting the production of complexes comprising any selected antigen in the sample and selected antigen-specific antibodies to said selected antigen; and
(c) means for determining production of the complexes.

### Claim 32

A method for producing antibodies specific for a selected antigen comprising:
(a) immunizing a host with an effective amount of an immunogenic composition comprising a conjugate antibody molecule comprising a monoclonal antibody moiety specific for a surface structure of antigen presenting cells genetically modified to contain at least one antigen moiety exclusively at at least one preselected site on said monoclonal antibody moiety, whereby said conjugate antibody molecule is capable of delivering said antigen moiety to the antigen presenting cells of a host and capable of eliciting an immune response to said antigen moiety in the host or a nucleic acid molecule comprising a first nucleotide sequence encoding a chain of a monoclonal antibody specific for a surface structure of antigen-presenting cells selected from the group consisting of the heavy chain and the light chain of the monoclonal antibody, a second nucleotide sequence encoding at least one antigen and a third nucleotide sequence comprising a promoter for eukaryotic cell expression of a fusion protein comprising said monoclonal antibody chain and said at least one antigen, wherein said at least one antigen is the selected antigen to produce antibodies specific for the selected antigen and
(b) isolating the antibodies from the host.

### Claim 33

A method of producing monoclonal antibodies specific for a selected antigen comprising:
(a) administering an immunogenic composition comprising a conjugate molecule comprising a monoclonal antibody moiety specific for a surface structure of antigen presenting cells genetically modified to contain at least one antigen moiety exclusively at at least one preselected site or said monoclonal antibody moiety, whereby said conjugate antibody molecule is capable of delivering said antigen moiety to the antigen presenting cells of a host and capable of eliciting an immune response to said antigen moiety in the host, or a nucleic acid molecule comprising a first nucleotide sequence encoding a chain of a monoclonal antibody specific for a surface structure of antigen-presenting cells selected from the group consisting of the heavy chain and the light chain of the monoclonal antibody, a second nucleotide sequence encoding at least one antigen and a third nucleotide sequence comprising a promoter for eukaryotic cell expression of a fusion protein comprising said monoclonal antibody chain and said at least one antigen, wherein said at least one antigen is the selected antigen to at least one mouse to produce at least one immunized mouse;
(b) removing B-lymphocytes from the at least one immunized mouse;
(c) fusing the B-lymphocytes from the at least one immunized mouse with myeloma cells, thereby producing hybridomas;
(d) cloning the hybridomas;
(e) selecting clones which produce anti-selected antigen antibody;
(f) culturing the anti-selected antigen antibody-producing clones; and then
(g) isolating anti-selected antigen antibodies from the cultures.
